355
Views
3
CrossRef citations to date
0
Altmetric
Original Articles

Efficacy and Safety of Adalimumab in Patients with Behçet Uveitis: A Systematic Review and Meta-Analysis

, MDORCID Icon, , MDORCID Icon, , MDORCID Icon & , PhDORCID Icon
Pages 89-97 | Received 08 Sep 2022, Accepted 06 Dec 2022, Published online: 10 Jan 2023

References

  • Evereklioglu C. Current concepts in the etiology and treatment of Behçet disease. Surv Ophthalmol. 2005;50(4):297–350. doi:10.1016/j.survophthal.2005.04.009.
  • Evereklioglu C. Managing the symptoms of Behçet’s disease. Expert Opin Pharmacother. 2004;5(2):317–328. doi:10.1517/14656566.5.2.317.
  • Azizlerli G, Akdağ Köse A, Sarıca R, et al. Prevalence of Behçet’s disease in Istanbul, Turkey. Int J Dermatol. 2003;42(10):803–806. doi:10.1046/j.1365-4362.2003.01893.x.
  • Krause I, Yankevich A, Fraser A, et al. Prevalence and clinical aspects of Behcet’s disease in the north of Israel. Clin Rheumatol. 2007;26(4):555–560. doi:10.1007/s10067-006-0349-4.
  • Kaçmaz RO, Kempen JH, Newcomb C, et al. Ocular inflammation in Behçet disease: incidence of ocular complications and of loss of visual acuity. Am J Ophthalmol. 2008;146(6):828–836. doi:10.1016/j.ajo.2008.06.019.
  • Kitaichi N, Miyazaki A, Iwata D, Ohno S, Stanford MR, Chams H. Ocular features of Behçet’s disease: an international collaborative study. Br J Ophthalmol. 2007;91(12):1579–1582. doi:10.1136/bjo.2007.123554.
  • Evereklioglu C, Er H, Türköz Y, Çekmen M. Serum levels of TNF-α, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet’s disease. Mediators Inflamm . 2002;11(2):87–93. doi:10.1080/09629350220131935.
  • Evereklioglu C, Borlu M. Sustained remission after infliximab in a child with vasculitis refractory to conventional immunosuppressives including interferon-α. Br J Ophthalmol. 2008;92(8):1034. doi:10.1136/bjo.2007.127522.
  • Atzeni F, Turiel M, Capsoni F, Doria A, Meroni P, Sarzi-puttini P. Autoimmunity and anti-TNF-α agents. Ann N Y Acad Sci. 2005;1051(1):559–569. doi:10.1196/annals.1361.100.
  • Jaffe GJ, Dick AD, Brézin AP, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016;375(10):932–943. doi:10.1056/NEJMoa1509852.
  • Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016;388(10050):1183–1192. doi:10.1016/S0140-6736(16)31339-3.
  • Evereklioglu C. Ocular Behçet disease: current therapeutic approaches. Curr Opin Ophthalmol. 2011;22(6):508–516. doi:10.1097/ICU.0b013e32834bbe91.
  • Leclercq M, Andrillon A, Maalouf G, et al. Anti-TNF-α versus tocilizumab in the treatment of refractory uveitic macular edema: a multicenter study from the French uveitis network. Ophthalmology. 2021. doi:10.1016/j.ophtha.2021.11.013.
  • Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg. 2021;88:105906. doi:10.1016/j.ijsu.2021.105906.
  • Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–605. doi:10.1007/s10654-010-9491-z.
  • Holladay JT. Proper Method for Calculating Average Visual Acuity. Vol 13. NJ: SLACK Incorporated Thorofare; 1997:388–391. doi: 10.3928/1081-597X-19970701-16.
  • Holladay JT. Visual acuity measurements. J Cataract Refract Surg. 2004;30(2):287–290. doi:10.1016/j.jcrs.2004.01.014.
  • Schulze-Bonsel K, Feltgen N, Burau H, Hansen L, Bach M. Visual acuities “hand motion” and “counting fingers” can be quantified with the Freiburg visual acuity test. Invest Ophthalmol Vis Sci. 2006;47(3):1236–1240. doi:10.1167/iovs.05-0981.
  • Group SoUNW. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140(3):509–516. doi:10.1016/j.ajo.2005.03.057.
  • Nussenblatt RB, Palestine AG, Chan -C-C, Roberge F. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology. 1985; 92(4):467–471.
  • Hogan MJ, Kimura SJ, Thygeson P. Signs and symptoms of uveitis: I. Anterior uveitis. Am J Ophthalmol. 1959;47(5):155–170. doi:10.1016/S0002-9394(14)78239-X.
  • Tugal-Tutkun I, Herbort CP, Khairallah M. Scoring of dual fluorescein and ICG inflammatory angiographic signs for the grading of posterior segment inflammation (dual fluorescein and ICG angiographic scoring system for uveitis). Int Ophthalmol. 2010;30(5):539–552. doi:10.1007/s10792-008-9263-x.
  • Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Bmj. 2003;327(7414):557–560. doi:10.1136/bmj.327.7414.557.
  • Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14(1):1–13. doi:10.1186/1471-2288-14-135.
  • Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res. 2018;27(6):1785–1805. doi:10.1177/0962280216669183.
  • Kunimi K, Usui Y, Asakage M, et al. Anti-TNF-alpha therapy for refractory uveitis associated with Behcet’s syndrome and sarcoidosis: a single center study of 131 patients. Ocul Immunol Inflamm. 2022;30(1):223–230. doi:10.1080/09273948.2020.1791346.
  • Yang SZ, Huang ZH, Liu XX, et al. Comparative study of adalimumab versus conventional therapy in sight-threatening refractory Behcet’s uveitis with vasculitis. Int Immunopharmacol. 2021;93:7. doi:10.1016/j.intimp.2021.107430.
  • Yang SZ, Huang ZH, Hu YW, et al. The efficacy of adalimumab as an initial treatment in patients with Behcet’s retinal vasculitis. Front Pharmacol. 2021;12:10.
  • Soheilian M, Ebrahimiadib N, Hedayatfar A, Hosseini M, Zarei M, Anjidani N. Efficacy of biosimilar adalimumab in the treatment of Behçet’s uveitis. Ocul Immunol Inflamm. 2021;30(6):1495–1500. doi:10.1080/09273948.2021.1900276.
  • Kim BH, Park UC, Park SW, Yu HG. Ultra-widefield fluorescein angiography to monitor therapeutic response to adalimumab in Behcet’s uveitis. Ocul Immunol Inflamm. 2021;30(6):1347–1353. doi:10.1080/09273948.2021.1872652.
  • Atienza-Mateo B, Martin-Varillas JL, Calvo-Rio V, et al. Comparative study of infliximab versus adalimumab in refractory uveitis due to Behcet’s disease: national multicenter study of 177 cases. Arthritis Rheumatol. 2019;71(12):2081–2089. doi:10.1002/art.41026.
  • Fabiani C, Sota J, Vitale A, et al. Cumulative retention rate of adalimumab in patients with Behçet’s disease-related uveitis: a four-year follow-up study. Br J Ophthalmoly. 2018;102(5):637–641. doi:10.1136/bjophthalmol-2017-310733.
  • Fabiani C, Vitale A, Emmi G, et al. Efficacy and safety of adalimumab in Behçet’s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol. 2017;36(1):183–189. doi:10.1007/s10067-016-3480-x.
  • Interlandi E, Leccese P, Olivieri I, Latanza L. Adalimumab for treatment of severe Behçet’s uveitis: a retrospective long-term follow-up study. Clin Experimental Rheumatol. 2014; 32(4 Suppl 84):S58–62.
  • Bawazeer A, Raffa LH, Nizamuddin. Clinical experience with adalimumab in the treatment of ocular Behcet disease. Ocul Immunol Inflamm. 2010;18(3):226–232. doi:10.3109/09273948.2010.483314.
  • Ahn JK, Yu HG, Chung H, Park YG. Intraocular cytokine environment in active Behçet uveitis. Am J Ophthalmol. 2006;142(3):429–434. e421. doi:10.1016/j.ajo.2006.04.016.
  • Hale S, Lightman S. Anti-TNF therapies in the management of acute and chronic uveitis. Cytokine. 2006;33(4):231–237. doi:10.1016/j.cyto.2005.12.012.
  • Whitcup SM, Sen HN. Whitcup and Nussenblatt’s Uveitis: Fundamentals and Clinical Practice. New York: Elsevier Health Sciences; 2021.
  • Dick AD, Forrester JV, Liversidge J, Cope AP. The role of tumour necrosis factor (TNF-α) in experimental autoimmune uveoretinitis (EAU). Prog Ret Eye Res. 2004;23(6):617–637. doi:10.1016/j.preteyeres.2004.06.005.
  • Rothova A, Suttorp-van Schulten M, Treffers WF, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996;80(4):332–336. doi:10.1136/bjo.80.4.332.
  • Markomichelakis NN, Halkiadakis I, Pantelia E, et al. Course of macular edema in uveitis under medical treatment. Ocul Immunol Inflamm. 2007;15(2):71–79. doi:10.1080/09273940701244509.
  • Gritz DC, Schwaber EJ, Wong IG. Complications of uveitis: the northern California epidemiology of uveitis study. Ocul Immunol Inflamm. 2018;26(4):584–594. doi:10.1080/09273948.2016.1247174.
  • Tomkins-Netzer O, Talat L, Bar A, et al. Long-term clinical outcome and causes of vision loss in patients with uveitis. Ophthalmology. 2014;121(12):2387–2392. doi:10.1016/j.ophtha.2014.07.007.
  • Hassan M, Karkhur S, Bae JH, et al. New therapies in development for the management of non-infectious uveitis: a review. Clin Exp Ophthalmol. 2019;47(3):396–417. doi:10.1111/ceo.13511.
  • Hu Y, Huang Z, Yang S, Chen X, Su W, Liang D. Effectiveness and safety of anti-tumor necrosis factor-alpha agents treatment in Behcets’ disease-associated uveitis: a systematic review and meta-analysis. Front Pharmacol. 2020;11:941. doi:10.3389/fphar.2020.00941.
  • Maccora I, Fusco E, Marrani E, Ramanan AV, Simonini G. Changing evidence over time: updated meta-analysis regarding anti-TNF efficacy in childhood chronic uveitis. Rheumatology. 2021;60(2):568–587. doi:10.1093/rheumatology/keaa595.
  • Ming S, Xie K, He H, Li Y, Lei B. Efficacy and safety of adalimumab in the treatment of non-infectious uveitis: a meta-analysis and systematic review. Drug Des Devel Ther. 2018;12:2005. doi:10.2147/DDDT.S160431.
  • Dick AD, Tundia N, Sorg R, et al. Risk of ocular complications in patients with noninfectious intermediate uveitis, posterior uveitis, or panuveitis. Ophthalmology. 2016;123(3):655–662. doi:10.1016/j.ophtha.2015.10.028.
  • Tugal-Tutkun I, Ozdal PC, Oray M, Onal S. Review for diagnostics of the year: multimodal imaging in Behçet uveitis. Ocul Immunol Inflamm. 2017;25(1):7–19. doi:10.1080/09273948.2016.1205100.
  • Díaz-Llopis M, Salom D, Garcia-de-Vicuña C, et al. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology. 2012;119(8):1575–1581. doi:10.1016/j.ophtha.2012.02.018.
  • Ali A, Ku JH, Suhler EB, Choi D, Rosenbaum JT. The course of retinal vasculitis. Br J Ophthalmol. 2014;98(6):785–789. doi:10.1136/bjophthalmol-2013-303443.
  • Fardet L, Kassar A, Cabane J, Flahault A. Corticosteroid-induced adverse events in adults. Drug Saf. 2007;30(10):861–881. doi:10.2165/00002018-200730100-00005.
  • Namba K, Kaburaki T, Tsuruga H, Ogawa Y, Iwashita E, Goto H. Long-term safety and effectiveness of adalimumab in Japanese patients with noninfectious intermediate, posterior, or panuveitis: post-marketing surveillance of 251 Patients. Ophthalmol Ther. 2022;11(3):1147–1161. doi:10.1007/s40123-022-00493-z.
  • Sonmez HK, Evereklioglu C, Gulmez Sevim D. Prompt and sustained suppression of intraocular inflammation with adalimumab in pediatric patients with non-infectious uveitis resistant to traditional managements: a 6-month follow-up research. Ocul Immunol Inflamm. 2022;1–5. [In Press]. doi:10.1080/09273948.2022.2139274.
  • Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behçet’s syndrome. Ann Rheum Dis. 2018;77(6):808–818. doi:10.1136/annrheumdis-2018-213225.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.